April 15, 2021
Video
Ryan Haumschild, PharmD, MS, MBA, provides insight on biosimilar adoption both in oncology and non-oncology practice settings.
April 13, 2021
The impact on biosimilar utilization in clinical practice caused by secondary patents of biologics and skinny labels of biosimilars is discussed.
April 08, 2021
Tim Peterson, PharmD, BCOP, leads the discussion on immunogenicity testing and lot-to-lot variability, including the potential impact on the safety and efficacy of reference biologics and their biosimilars.
April 06, 2021
A discussion on what it means for a biosimilar to have “interchangeability” status and its potential impact on biosimilar adoption in clinical practice.
April 02, 2021
Ryan Haumschild, PharmD, MS, MBA, defines biosimilars in oncology and what distinguishes them from a reference biologic.
December 01, 2020
Pharmacy Times® interviewed Chad Landmon, JD, of Axinn, Veltrop & Harkrider, on the arguments presented to the Supreme Court on whether a legislative change to the Affordable Care Act makes the law unconstitutional.
November 19, 2020
Article
Institutions are replacing innovator biologics with their biosimilars, often to take advantage of the financial benefits.
October 07, 2020
Study findings align with recent recommendations from the National Comprehensive Cancer Network for preventing febrile neutropenia in patients with early-stage breast cancer.
August 07, 2020
Cancer care providers have increasingly been using biosimilars on a case-by-case basis with patients.
July 19, 2020
Cancer medications contribute substantially to the cost of health care in the United States, with 8 of the 10 most expensive drugs indicated for the treatment of cancer
